New England Journal Of Medicine Article on TKT's Non-Viral Gene Therapy System Demonstrates Promising Clinical Effects in Patients With Severe Hemophilia A.
CAMBRIDGE, Mass., June 7 /PRNewswire/ -- Investigators at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts reported results from the first human investigation of hemophilia A gene therapy. The study, which appears in today's issue of the New England Journal of Medicine (NEJM), demonstrates that...

BP to Evaluate Divestment Alternatives for Vysis.
NEW YORK, July 11 /PRNewswire/ -- BP p.l.c. (NYSE: BP) today filed an amended Form 13-D with respect to its 65.5% share ownership in Vysis, Inc. (Nasdaq: VYSI) ("Vysis") stating that it does not consider this stake to be strategic. As a result BP is...

TKT Announces Date of Second Quarter 2001 Financial Results and Conference Call.
CAMBRIDGE, Mass., July 20 /PRNewswire/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX) will release second quarter 2001 financial results on Tuesday, July 31, 2001 after the close of U.S. financial markets. In connection with this announcement, TKT will host a conference call and live audio webcast on Tuesday,...

TKT Announces New Executive Appointment and Promotion.
CAMBRIDGE, Mass., Feb. 27 /PRNewswire/ -- Transkaryotic Therapies, Inc. (Nasdaq: TKTX) announced today the appointment of Anthony S. Murabito as Vice President, Management Information Systems. In this role, Mr. Murabito has overall responsibility for TKT's information technology and telecommunications systems, including the evaluation, introduction, and integration of...

Vysis Expands Scientific Advisory Board.
Noted Oncologists and Research Scientists Bring Strong National and International Capability DOWNERS GROVE, Ill., April 23 /PRNewswire/ -- Vysis, Inc. (Nasdaq: VYSI), a developer and marketer of DNA-based clinical products providing information for genomic disease management, announced today that it has expanded its...

IMPROVEMENT IN CARDIAC FUNCTION DEMONSTRATED FOLLOWING TREATMENT WITH REPLAGAL.
PR Newswire, London, May 18. This press release is transmitted on behalf of TransKaryotic Therapies Inc. Vienna, Austria - Transkaryotic Therapies, Inc. (Nasdaq: TKTX) today announced positive results in a pivotal clinical trial of its investigational enzyme replacement therapy, Replagal(TM) (agalsidase alfa), for the treatment...

Vysis, Inc. Invites You to Join Its Virtual CEO Summit Webcast.
CHICAGO, May 21 /PRNewswire/ -- In conjunction with Vysis' (Nasdaq: VYSI) Virtual CEO Summit slide presentation, you are invited to listen to its webcast that will be broadcast live over the Internet on Wednesday, May 23 at 10 a.m. EDT with John Bishop, President & CEO of...

Caremark Rx Announces Second-Quarter Earnings Release Date July 31, 2001.
BIRMINGHAM, Ala., July 16 /PRNewswire/ -- Caremark Rx, Inc. (NYSE: CMX) today announced its intention to release its second-quarter earnings on Tuesday, July 31, 2001. In addition, on the same date management will hold an investor conference call to discuss the quarterly results and the general operations...

Caremark Rx Announces First Quarter Earnings Release Date April 25, 2001.
BIRMINGHAM, Ala., April 16 /PRNewswire/ -- Caremark Rx, Inc. (NYSE: CMX) today announced its intention to release its first quarter earnings on Wednesday, April 25, 2001. In addition, on the same date management will hold an investor conference call to discuss the quarterly results and the general...

Caremark Rx Scheduled to Hold Investor Conference Tuesday, June 5, 2001.
BIRMINGHAM, Ala., June 1 /PRNewswire/ -- Caremark Rx, Inc. (NYSE: CMX) today announced its intention to host an Investor Conference, Tuesday, June 5, 2001, where management will make a presentation regarding the Company followed by a tour of one of its mail-order pharmacies. Due to limited space,...